Scientists find gene target that may protect against Crohn’s disease and ulcerative colitis

The discovery by a six-member Inflammatory Bowel Disease (IBD) Genetics Consortium of a genetic risk factor for IBD has been reported in Science Express, the online publication of the journal Science. According to one of the Canadian principal investigators, director of the Laboratory in Genetics and Genomic Medicine of Inflammation at the Montreal Heart Institute, Dr. John D. Rioux, “This discovery may lead to a paradigm shift in our thinking from ‘genetics of diseases to genetics of health’, particularly as concerns Crohn’s Disease and Ulcerative Colitis.”

Inflammatory bowel disease, or IBD, describes two similar yet distinct conditions called Crohn’s disease and ulcerative colitis. These diseases affect the digestive system and cause the intestinal tissue to become inflamed, form sores and bleed easily. Symptoms include abdominal pain, cramping, fatigue and diarrhea.

Crohn’s disease may affect the gastrointestinal tract, from the mouth to the anus, and while Crohn’s disease can not be cured by drugs or surgery, either may relieve symptoms.

In Canada, an estimated 170,000 Canadian men and women suffer from IBD, most frequently between the ages of 15-25, or 45-55. It is particularly difficult for children and young adults since it often affects a person’s self-concept. IBD is found throughout the world. However, it appears to be most common in North America and northern Europe; Canada having one of the highest incidence rates of IBD in the world. (1) In the U.S., more than 1 million Americans have Crohn’s or colitis.

Since IBD tends to run in families and is more frequent in certain populations, especially Ashkenazi Jews, scientists have long suspected a significant genetic component. Although previous genetic studies found a link between Crohn’s disease and mutations in a gene known as CARD15, those mutations alone are not considered to account for the entire genetic component of disease.

According to senior author Judy H. Cho, M.D., associate professor in the departments of Medicine and Genetics at Yale School of Medicine, the findings highlight a major inflammatory pathway and may change our thinking about disease-associated genetic variation. “This pathway is particularly intriguing because we appear to have identified a gene variant that protects against development of IBD,” said Dr. Cho, who is also director of the Inflammatory Bowel Disease Center at Yale.

While mutations of the gene which codes for a receptor in a major inflammatory pathway are strongly associated with Crohn’s disease, surprisingly, Consortium researchers report that one type of mutation may confer significant protection and identify potential targets for drugs therapies for the management of Crohn’s disease and ulcerative colitis.

To identify additional genes that are associated with IBD, the international team of researchers scanned the genome – some 22,000 – by testing more than 300,000 nucleotide polymorphisms, or SNPs, in people with Crohn’s disease, and a similar number of people without IBD. The scan led to an unexpected discovery.

Although several polymorphisms were associated with a significantly increased risk of developing IBD, one appeared to confer a very strong protection against IBD.

“Of all the SNPs we studied in people with and without IBD, this protective SNP was the most statistically significant finding in our study. So, it took us a bit by surprise,” said first author, Richard H. Duerr, M.D., associate professor of medicine and human genetics, University of Pittsburgh. “What it means in terms of improving treatments for IBD patients, we are not sure yet.”

Nonetheless, members of the Consortium are attempting to tease out the specific downstream effects of this protective polymorphism. Yet, because IL-23 plays an important role in activating inflammation, including in the organs of the digestive tract, it could be an extremely important target for improving the management of Crohn’s disease and other IBDs.

“Recent studies in mice in which the gene for IL-23 was deleted demonstrated that it is essential for triggering chronic intestinal inflammation. Such evidence, combined with the current discovery, suggests therapies that target the IL-23 pathway may lead to more individualized, better-directed therapies for IBDs. In fact, blocking the activity of IL-23 or manipulating its pathway may be an effective way to manage IBD,” said Dr. Rioux. “I am confident that the future genetic studies by this collaborative group will continue to improve our understanding of these and other chronic inflammatory diseases,” he added.

Source: University of Montreal


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s